Logo image of ALVR

ALLOVIR INC (ALVR) Stock Fundamental Analysis

NASDAQ:ALVR - Nasdaq - US0198181036 - Common Stock - Currency: USD

9.81  +0.15 (+1.55%)

Fundamental Rating

3

Overall ALVR gets a fundamental rating of 3 out of 10. We evaluated ALVR against 560 industry peers in the Biotechnology industry. ALVR has a great financial health rating, but its profitability evaluates not so good. ALVR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALVR has reported negative net income.
ALVR had a negative operating cash flow in the past year.
In the past 5 years ALVR always reported negative net income.
In the past 5 years ALVR always reported negative operating cash flow.
ALVR Yearly Net Income VS EBIT VS OCF VS FCFALVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

ALVR has a Return On Assets (-49.57%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -51.87%, ALVR is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
Industry RankSector Rank
ROA -49.57%
ROE -51.87%
ROIC N/A
ROA(3y)-73.56%
ROA(5y)-51.32%
ROE(3y)-94.03%
ROE(5y)-64.29%
ROIC(3y)N/A
ROIC(5y)N/A
ALVR Yearly ROA, ROE, ROICALVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALVR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVR Yearly Profit, Operating, Gross MarginsALVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

ALVR has less shares outstanding than it did 1 year ago.
ALVR has less shares outstanding than it did 5 years ago.
There is no outstanding debt for ALVR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALVR Yearly Shares OutstandingALVR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALVR Yearly Total Debt VS Total AssetsALVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ALVR has an Altman-Z score of -3.17. This is a bad value and indicates that ALVR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.17, ALVR perfoms like the industry average, outperforming 47.89% of the companies in the same industry.
ALVR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.17
ROIC/WACCN/A
WACCN/A
ALVR Yearly LT Debt VS Equity VS FCFALVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 22.63 indicates that ALVR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 22.63, ALVR belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
ALVR has a Quick Ratio of 22.63. This indicates that ALVR is financially healthy and has no problem in meeting its short term obligations.
ALVR's Quick ratio of 22.63 is amongst the best of the industry. ALVR outperforms 96.49% of its industry peers.
Industry RankSector Rank
Current Ratio 22.63
Quick Ratio 22.63
ALVR Yearly Current Assets VS Current LiabilitesALVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.78% over the past year.
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALVR will show a very strong growth in Earnings Per Share. The EPS will grow by 20.08% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.66%
EPS Next 2Y35.01%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALVR Yearly Revenue VS EstimatesALVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 200K 400K 600K 800K 1M
ALVR Yearly EPS VS EstimatesALVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVR Price Earnings VS Forward Price EarningsALVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVR Per share dataALVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as ALVR's earnings are expected to grow with 20.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.01%
EPS Next 3Y20.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALVR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLOVIR INC

NASDAQ:ALVR (3/18/2025, 8:21:54 PM)

9.81

+0.15 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-12 2025-05-12
Inst Owners42.88%
Inst Owner Change-99.2%
Ins Owners6.37%
Ins Owner Change-0.14%
Market Cap49.44M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-24.69
FCFYN/A
OCF(TTM)-24.69
OCFYN/A
SpS0
BVpS22.48
TBVpS22.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.57%
ROE -51.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.56%
ROA(5y)-51.32%
ROE(3y)-94.03%
ROE(5y)-64.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.63
Quick Ratio 22.63
Altman-Z -3.17
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.49%
EPS Next Y69.66%
EPS Next 2Y35.01%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.06%
EBIT Next 3Y18.66%
EBIT Next 5YN/A
FCF growth 1Y12.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.39%
OCF growth 3YN/A
OCF growth 5YN/A